Detalhe da pesquisa
1.
Tape strips detect molecular alterations and cutaneous biomarkers in skin of patients with hidradenitis suppurativa.
J Am Acad Dermatol
; 90(4): 749-758, 2024 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-38049071
2.
IL4Rα and IL17A Blockade Rescue Autoinflammation in SOCS1 Haploinsufficiency.
J Clin Immunol
; 44(1): 36, 2023 12 29.
Artigo
Inglês
| MEDLINE | ID: mdl-38157076
3.
Halogen halos: Report of an early histopathologic finding in iododerma.
J Cutan Pathol
; 50(9): 806-809, 2023 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-37394806
4.
Off-Label Use of Janus Kinase Inhibitors in Inflammatory Cutaneous Diseases.
J Drugs Dermatol
; 22(12): 1183-1190, 2023 Dec 01.
Artigo
Inglês
| MEDLINE | ID: mdl-38051858
5.
Baseline IL-22 expression in patients with atopic dermatitis stratifies tissue responses to fezakinumab.
J Allergy Clin Immunol
; 143(1): 142-154, 2019 01.
Artigo
Inglês
| MEDLINE | ID: mdl-30121291
6.
Treatment of recalcitrant psoriasis and psoriatic arthritis with a combination of a biologic plus an oral JAK or TYK2 inhibitor: a case series.
Ann Rheum Dis
; 2024 May 16.
Artigo
Inglês
| MEDLINE | ID: mdl-38754982
7.
Use of systemic Janus kinase inhibitors for dermatologic indications in the elderly: A retrospective study of 67 cases.
J Am Acad Dermatol
; 90(4): 816-819, 2024 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-38072127
8.
Use of dual biologic therapy targeting the Th2 and Th17 axes simultaneously to treat patients with atopic dermatitis and concomitant psoriasis, psoriatic arthritis, or inflammatory bowel disease.
J Am Acad Dermatol
; 2024 Mar 15.
Artigo
Inglês
| MEDLINE | ID: mdl-38494153
9.
Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trial.
J Am Acad Dermatol
; 78(5): 872-881.e6, 2018 05.
Artigo
Inglês
| MEDLINE | ID: mdl-29353025
10.
Efficacy and safety of ustekinumab treatment in adults with moderate-to-severe atopic dermatitis.
Exp Dermatol
; 26(1): 28-35, 2017 01.
Artigo
Inglês
| MEDLINE | ID: mdl-27304428
11.
A mild topical steroid leads to progressive anti-inflammatory effects in the skin of patients with moderate-to-severe atopic dermatitis.
J Allergy Clin Immunol
; 138(1): 169-178, 2016 07.
Artigo
Inglês
| MEDLINE | ID: mdl-26948076
12.
Petrolatum: Barrier repair and antimicrobial responses underlying this "inert" moisturizer.
J Allergy Clin Immunol
; 137(4): 1091-1102.e7, 2016 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-26431582
13.
Severe atopic dermatitis is characterized by selective expansion of circulating TH2/TC2 and TH22/TC22, but not TH17/TC17, cells within the skin-homing T-cell population.
J Allergy Clin Immunol
; 136(1): 104-115.e7, 2015 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-25748064
14.
Patients with atopic dermatitis have attenuated and distinct contact hypersensitivity responses to common allergens in skin.
J Allergy Clin Immunol
; 135(3): 712-20, 2015 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-25583101
15.
Cyclosporine in patients with atopic dermatitis modulates activated inflammatory pathways and reverses epidermal pathology.
J Allergy Clin Immunol
; 133(6): 1626-34, 2014 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-24786238
16.
Efficacy of risankizumab across subgroups in patients with active psoriatic arthritis: a post hoc integrated analysis of the phase 3 KEEPsAKE 1 and KEEPsAKE 2 randomized controlled trials.
J Dermatolog Treat
; 35(1): 2342383, 2024 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-38632977
17.
Comparing Achievement of National Psoriasis Foundation Treatment Targets among Patients with Plaque Psoriasis Treated with Ixekizumab versus Other Biologics in Clinical and Real-World Studies.
Dermatol Ther (Heidelb)
; 14(4): 933-952, 2024 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-38521874
18.
Enthesitis and Dactylitis Resolution with Risankizumab for Active Psoriatic Arthritis: Integrated Analysis of the Randomized KEEPsAKE 1 and 2 Trials.
Dermatol Ther (Heidelb)
; 2024 May 13.
Artigo
Inglês
| MEDLINE | ID: mdl-38739215
19.
Brepocitinib, Zimlovisertib, and Ropsacitinib in Hidradenitis Suppurativa.
NEJM Evid
; 3(3): EVIDoa2300155, 2024 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-38335032
20.
Rheumatic manifestations of euthyroid, anti-thyroid antibody-positive patients.
Rheumatol Int
; 33(7): 1745-52, 2013 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-23292189